Jens MD - Zealand Pharma Head Pharmacology

All Insiders Denmark . 
Stock . Zealand Pharma AS . Stakeholders . Insider . Jens MD
ZEAL Stock  DKK 730.00  3.00  0.41%   

Insider

Jens MD is Head Pharmacology of Zealand Pharma AS
Phone45 88 77 36 00
Webhttps://www.zealandpharma.com

Zealand Pharma Management Efficiency

The company has return on total asset (ROA) of (0.4816) % which means that it has lost $0.4816 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (1.4412) %, meaning that it generated substantial loss on money invested by shareholders. Zealand Pharma's management efficiency ratios could be used to measure how well Zealand Pharma manages its routine affairs as well as how well it operates its assets and liabilities.
Zealand Pharma AS has accumulated 647.91 M in total debt with debt to equity ratio (D/E) of 0.1, which may suggest the company is not taking enough advantage from borrowing. Zealand Pharma AS has a current ratio of 4.11, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Zealand Pharma until it has trouble settling it off, either with new capital or with free cash flow. So, Zealand Pharma's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Zealand Pharma AS sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Zealand to invest in growth at high rates of return. When we think about Zealand Pharma's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

INSIDER Age

Britt JensenAmbu AS
50
Peter RosGenmab AS
N/A
Peter KristensenGenmab AS
45
Christian HoughtonALK Abell AS
N/A
Mette MEngFLSmidth Co
56
Thomas SchmidtAmbu AS
52
Thomas HenriksenAmbu AS
50
Anders PedersenGenmab AS
68
Carsten HellmannALK Abell AS
59
Cori PetersenFLSmidth Co
54
Sofie LindbergFLSmidth Co
N/A
Judith KlimovskyGenmab AS
63
Mikkel WagnerAmbu AS
N/A
Henrik MScBavarian Nordic
58
Laurence MoerloozeBavarian Nordic
59
Henrik JacobiALK Abell AS
58
Rolf HoffmannGenmab AS
60
Katja ThalundALK Abell AS
54
Judith MDGenmab AS
65
Pr MDALK Abell AS
N/A
Nicolai ThomsenAmbu AS
N/A
Zealand Pharma AS, a biotechnology company, engages in the discovery, design, and development of peptide-based medicines in Denmark. The company was founded in 1997 and is headquartered in Copenhagen, Denmark. Zealand Pharma operates under Biotechnology classification in Denmark and is traded on Copenhagen Stock Exchange. It employs 360 people. Zealand Pharma AS (ZEAL) is traded on Copenhagen Exchange in Denmark and employs 203 people.

Management Performance

Return On Equity-1.44
Return On Asset-0.48

Zealand Pharma AS Leadership Team

Elected by the shareholders, the Zealand Pharma's board of directors comprises two types of representatives: Zealand Pharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Zealand. The board's role is to monitor Zealand Pharma's management team and ensure that shareholders' interests are well served. Zealand Pharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Zealand Pharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
Henriette Wennicke, Chief Officer
Lani Morvan, Investor Officer
Adam MD, Pres CEO
Hanne Bak, RD Director
Mads Kronborg, Head Communication
Ravinder Chahil, Sr Counsel
Christina Bredal, VP Organization
Danilo Verge, Head Affairs
Ivan Moller, Chief Officer
Jens MD, Head Pharmacology

Zealand Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Zealand Pharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity-1.44
Return On Asset-0.48
Operating Margin(3.82) %
Current Valuation10.33 B
Shares Outstanding51.28 M
Shares Owned By Insiders0.07 %
Shares Owned By Institutions56.21 %
Price To Earning12.66 X
Price To Book27.77 X
Price To Sales36.73 X

Pair Trading with Zealand Pharma

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Zealand Pharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Zealand Pharma will appreciate offsetting losses from the drop in the long position's value.

Moving together with Zealand Stock

  0.73NOVO-B Novo Nordisk ASPairCorr
  0.73GMAB Genmab ASPairCorr
  0.74ALK-B ALK Abell ASPairCorr
  0.81BAVA Bavarian NordicPairCorr

Moving against Zealand Stock

  0.59MAERSK-A AP MllerPairCorr
  0.58MAERSK-B AP MllerPairCorr
  0.52DSV DSV Panalpina ASPairCorr
The ability to find closely correlated positions to Zealand Pharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Zealand Pharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Zealand Pharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Zealand Pharma AS to buy it.
The correlation of Zealand Pharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Zealand Pharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Zealand Pharma AS moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Zealand Pharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Other Information on Investing in Zealand Stock

Zealand Pharma financial ratios help investors to determine whether Zealand Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Zealand with respect to the benefits of owning Zealand Pharma security.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY